Clinical Trials Browser

Completed × Observational × pembrolizumab × Clear all

NCT07192926 2026-02-20

SARCO-CTI

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT06345183 2025-11-06

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

NCT06771674 2025-09-09

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT07015333 2025-06-11

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Squamous Cell Carcinoma of Head and Neck

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04682587 2025-01-03

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

481 enrolled 14 charts

Carcinoma, Renal Cell

NCT02791594 2024-11-08

Imaging FDG Flare in Melanoma

21 enrolled 10 charts

Melanoma

NCT06607393 2024-09-23

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06585189 2024-09-05

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02600169 2024-05-06

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

Melanoma

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

NCT05908799 2023-09-13

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05611229 2023-04-06

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Melanoma

NCT02909348 2023-03-02

PASIP

Melanoma, Neoplasms

NCT03453892 2023-02-16

ST-ICI

Neoplasm Metastasis

NCT05714371 2023-02-06

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

NCT03197636 2022-03-03

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

Melanoma

NCT05023837 2022-01-25

Esporta

Uncommon Pathological Types of Lung Cancer

NCT04076228 2020-09-02

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

Carcinoma, Non-Small-Cell Lung

NCT03695835 2020-07-22

NIRPA

GastrointestinalGenitourinaryThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms